Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:59 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Oral 6R-BH4 for the Treatment of Isolated Systolic Hypertension and Endothelial Dysfunction
NCT00802893 · Johns Hopkins University · PHASE2 · terminated · last registry update 2017-08-21 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “We were unable to recruit any subjects into this study so no subjects completed the protocol. Therefore, we are unable to provide any conclusions.” | – | Registry record, Johns Hopkins University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PAH within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2018-02-22Also stopped (terminated): BioMarin Pharmaceutical, Sapropterin + Placebo (NCT01977820)
- 2018-01-10Results posted on the registry: Augusta University, BH4 5mg + BH4 20mg (NCT01772758)
- 2017-09-13Results posted on the registry: New York State Psychiatric Institute, Kuvan + Multivitamin (NCT01706965)
- 2017-07-25Results posted on the registry: Augusta University, Tetrahydrobiopterin (BH4) (NCT01398943)
- 2017-03-29Results posted on the registry: Stanford University, sapropterin dihydrochloride (NCT01135186)
- 2016-11-18Results posted on the registry: University of Southern California, Kuvan (NCT01617070)
- 2016-10-18Results posted on the registry: University of Michigan, 6R BH4 (NCT00625820)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision